Biomarker-driven clinical trials are becoming more complex as precision medicine expands across therapeutic areas. Multi-analyte algorithms, blood-based assays, spatial biology and companion diagnostics are changing how patients are selected, monitored and stratified. This webinar will explore how precision biomarkers can support patient stratification, trial enrichment and clinical implementation.
A featured scientific case study will examine how multi-analyte biomarker strategies can improve patient stratification compared with single-marker approaches in Alzheimer's disease, illustrating how multidimensional biological information may reduce diagnostic uncertainty, identify patients earlier in the disease continuum and support more effective clinical trial enrichment. Additional examples from spatial biology and companion diagnostic development will demonstrate how tissue biomarker workflows are also increasingly supporting precision medicine programs across therapeutic areas.
Attendees will gain practical insights into the operational requirements needed to transform emerging biomarker discoveries into trial-ready solutions, from assay development and validation through clinical implementation, while exploring how integrated laboratory partnerships can help reduce development risk, improve data quality and support successful execution of modern biomarker-driven clinical trials.
Register for this webinar to learn how precision biomarkers can improve patient stratification, clinical trial enrichment and trial-ready biomarker implementation.
Who Should Attend
This webinar will appeal to:
Clinical Development leaders
Translational Medicine Scientists
Biomarker Strategy teams
Clinical Operations professionals
Precision Medicine and Companion Diagnostic teams
Medical Directors
Clinical Laboratory Scientists
Neuroscience Drug Development teams
Oncology Translational Research teams
Pharmaceutical and Biotechnology Program leaders
CRO Scientific leadership
Clinical Biomarker Directors
What You Will Learn
Attendees will learn:
Why biomarker innovation increasingly depends on operational excellence, not analytical performance alone
How multi-analyte biomarker strategies can improve patient stratification and clinical trial enrichment when compared with traditional single-marker approaches
Best practices for translating discovery biomarkers into analytically validated trial-ready assays
How blood-based biomarkers, spatial biology and regulatory-grade laboratory operations can support precision medicine across the clinical development continuum
Register free on Xtalks:
https://xtalks.com/webinars/advance-clinical-trial-enrichment-with-operational-precision-biomarkers/
